Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Return on Sales (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Return on Sales for 6 consecutive years, with 0.15% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales fell 20.0% to 0.15% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.05%, a 12.0% increase, with the full-year FY2025 number at 0.05%, up 12.0% from a year prior.
  • Return on Sales was 0.15% for Q4 2025 at GeneDx Holdings, down from 0.07% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 63.93% in Q2 2021 to a low of 5.03% in Q4 2022.
  • A 5-year average of 2.11% and a median of 0.57% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: crashed -6631bps in 2022, then skyrocketed 458bps in 2023.
  • GeneDx Holdings' Return on Sales stood at 0.7% in 2021, then plummeted by -624bps to 5.03% in 2022, then skyrocketed by 91bps to 0.45% in 2023, then soared by 113bps to 0.06% in 2024, then tumbled by -358bps to 0.15% in 2025.
  • Per Business Quant, the three most recent readings for WGS's Return on Sales are 0.15% (Q4 2025), 0.07% (Q3 2025), and 0.11% (Q2 2025).